NEW YORK (GenomeWeb News) – Epigenomics today said that revenues in its second quarter increased 120 percent.

The German molecular diagnostic firm reported revenues of €343,000 ($457,000) for the three months ended June 30, up from €157,000 a year ago. Products sales more than doubled to €164,000 from €73,000 in the year-ago period, while licensing income retreated to €59,000 from €83,000.

The firm took in €120,000 in R&D income, compared to none a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.